Transgene SA
Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. It is involved in developing TG4050, a therapeutic vaccine that is in phase I clini…
Biotechnology
FR, Illkirch-Graffenstaden [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
1
Financial Health
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| Current Ratio | 0.00 | 1.79 | 1.79 | |
| Debt/Assets | n.A. | n.A. | n.A. | |
| Debt/Equity | n.A. | n.A. | n.A. | |
| Net Debt/EBITDA | 1371.68 | 0.85 | -0.06 | |
| Naive Interpretation | member | |||
2
Per Share
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| Book Value | 0.83 | 0.16 | 0.15 | |
| Cash | 0.83 | 0.16 | 0.15 | |
| Capex | -109.63 | -0.01 | < 0.005 | |
| Free Cash Flow | -105.50 | -0.19 | -0.09 | |
| Revenue | -98.20 | < 0.005 | 0.02 | |
| Naive Interpretation | member | |||
3
Profitability
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| Gross Margin | -7087.81 | -249.34 | -3.47 | |
| Operating Margin | -13429.92 | -633.11 | -4.68 | |
| ROA | -100.00 | -0.14 | -0.07 | |
| ROE | -100.00 | -0.41 | -0.21 | |
| ROIC | -209.59 | -0.72 | -0.23 | |
| Naive Interpretation | member | |||
4
Valuation
The "Valuation Entry" for the Focus of TNG.PA is permitted for members.
5
Growth
The "Growth Entry" for the Focus of TNG.PA is permitted for members.
6
Leverage & Liquidity